In a phase II study of T-DM1 carried out with 15 relapsed HER2-positive NSCLC (IHC 3+, IHC 2+/FISH+, or exon 20 mutations), only one HER2-mutant patient achieved a PR (global ORR = 6.7%). Here, ERBB2 is linked to non-small cell lung carcinoma.